GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Redhill Biopharma Ltd (NAS:RDHL) » Definitions » Forward PE Ratio

Redhill Biopharma (Redhill Biopharma) Forward PE Ratio : 0.00 (As of Apr. 29, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Redhill Biopharma Forward PE Ratio?

Redhill Biopharma's Forward PE Ratio for today is 0.00.

Redhill Biopharma's PE Ratio without NRI for today is 0.00.

Redhill Biopharma's PE Ratio for today is 0.00.


Redhill Biopharma Forward PE Ratio Historical Data

The historical data trend for Redhill Biopharma's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redhill Biopharma Forward PE Ratio Chart

Redhill Biopharma Annual Data
Trend 2020-11
Forward PE Ratio
1,428.57

Redhill Biopharma Quarterly Data
Forward PE Ratio

Competitive Comparison of Redhill Biopharma's Forward PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Redhill Biopharma's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Redhill Biopharma's Forward PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Redhill Biopharma's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Redhill Biopharma's Forward PE Ratio falls into.



Redhill Biopharma Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Redhill Biopharma  (NAS:RDHL) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Redhill Biopharma Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Redhill Biopharma's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Redhill Biopharma (Redhill Biopharma) Business Description

Traded in Other Exchanges
Address
21 Ha’arba’a Street, Tel Aviv, ISR, 6473921
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults, Talicia for the treatment of Helicobacter pylori infection in adults, and Aemcolo for the treatment of travelers' diarrhea in adults. Its key clinical late-stage development programs include RHB-104 for Crohn's disease; RHB-204, for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) with positive results from a first Phase 3 study for acute gastroenteritis and gastritis; Opaganib (Yeliva); RHB-106, an encapsulated bowel preparation and RHB-107, a Phase 2-stage serine protease inhibitor targeting cancer and inflammatory gastrointestinal diseases.